BioArctic (BIOA B.ST) Stock Price
BioArctic Price
Revenue has compounded at 47.3% per year over the past 10 years to 2.00 B SEK. Earnings per share have grown at 75.5% per year over the last 10 years. BioArctic's net margin stands at 51.1%, up from -517.5% several years earlier. BioArctic currently offers a dividend yield of about 0.47%. The payout ratio is around 149% of earnings. Analysts set a median price target of 345.27 SEK, implying 8.5% above the current price. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 21% above its 52-week low.
BioArctic stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of BioArctic over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BioArctic stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BioArctic's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | BioArctic Price |
|---|---|
| 9/24/2026 | 318.20 SEK |
| 9/23/2026 | 322.00 SEK |
| 9/22/2026 | 322.20 SEK |
| 9/21/2026 | 320.60 SEK |
| 9/18/2026 | 328.00 SEK |
| 9/17/2026 | 324.60 SEK |
| 9/16/2026 | 320.80 SEK |
| 9/15/2026 | 321.80 SEK |
| 9/14/2026 | 324.40 SEK |
| 9/11/2026 | 319.60 SEK |
| 9/10/2026 | 326.80 SEK |
| 9/9/2026 | 328.00 SEK |
| 9/8/2026 | 331.20 SEK |
| 9/7/2026 | 330.00 SEK |
| 9/4/2026 | 334.00 SEK |
| 9/3/2026 | 346.20 SEK |
| 9/2/2026 | 326.40 SEK |
| 9/1/2026 | 320.20 SEK |
| 8/31/2026 | 319.80 SEK |
| 8/28/2026 | 335.60 SEK |
| 8/27/2026 | 325.40 SEK |
| 8/26/2026 | 322.00 SEK |
| 8/25/2026 | 345.00 SEK |
| 8/21/2026 | 335.60 SEK |
| 8/20/2026 | 337.20 SEK |
| 8/19/2026 | 326.60 SEK |
| 8/18/2026 | 322.60 SEK |
| 8/17/2026 | 323.00 SEK |
| 8/14/2026 | 319.60 SEK |
| 8/13/2026 | 327.00 SEK |
BioArctic Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
BioArctic Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB SEK |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB SEK |
| EBITB SEK |
| EBIT MARGIN% |
| NET INCOMEB SEK |
| NET INCOME GROWTH% |
| DIVIDENDDIV.SEK |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.04 | 0.11 | 0.14 | 0.71 | 0.28 | 0.06 | 0.02 | 0.23 | 0.62 | 0.26 | 2.00 | 1.54 | 1.95 | 2.28 | 3.44 |
| – | 156.10 | 33.33 | 409.29 | -60.59 | -77.94 | -62.90 | 891.30 | 169.74 | -58.21 | 677.82 | -22.76 | 26.10 | 17.00 | 50.97 |
| 100.00 | 100.00 | 100.00 | 79.66 | 74.38 | 19.35 | -134.78 | 67.11 | 85.53 | 89.49 | 97.00 | 97.00 | 97.00 | 97.00 | 97.00 |
| 0.04 | 0.11 | 0.14 | 0.57 | 0.21 | 0.01 | -0.03 | 0.15 | 0.53 | 0.23 | 1.94 | 1.50 | 1.89 | 2.21 | 3.34 |
| – | 0.07 | 0.02 | 0.49 | 0.11 | -0.09 | -0.14 | -0.01 | 0.25 | -0.23 | 1.37 | 0.33 | 0.82 | 1.50 | 2.60 |
| 9.76 | 70.48 | 13.57 | 68.02 | 40.21 | -137.10 | -604.35 | -4.39 | 40.98 | -88.72 | 68.43 | 21.18 | 42.01 | 66.02 | 75.72 |
| – | 0.06 | 0.02 | 0.38 | 0.09 | -0.07 | -0.12 | -0.01 | 0.23 | -0.18 | 1.02 | 0.51 | 0.61 | 0.80 | 2.23 |
| – | 1,800.00 | -73.68 | 2,440.00 | -76.90 | -177.27 | 75.00 | -90.76 | -2,181.82 | -177.29 | -677.40 | -50.39 | 20.91 | 31.00 | 178.21 |
| – | – | – | – | 1.50 | – | – | – | – | – | – | 2.00 | 2.40 | 2.88 | – |
| – | – | – | – | – | – | – | – | – | – | – | – | 20.00 | 20.00 | – |
| 88.72 | 88.06 | 88.06 | 89.16 | 88.06 | 88.06 | 107.61 | 88.10 | 88.31 | 88.38 | 88.28 | 88.28 | 88.28 | 88.28 | 88.28 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales BioArctic generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BioArctic retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BioArctic's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares BioArctic has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BioArctic's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
BioArctic stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
BioArctic Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
BioArctic business model & stock analysis
BioArctic SWOT Analysis
Strengths
BioArctic AB benefits from several strengths that contribute to its success in the market. These include:
- Strong expertise in biotechnology and neuroscience research
- Robust portfolio of innovative therapies and products
- Positive reputation and recognition in the industry
- Strong intellectual property protection for its discoveries
- Well-established collaborations with reputable organizations
Weaknesses
Despite its strengths, BioArctic AB also faces certain weaknesses that could pose challenges to its growth and competitiveness:
- Relatively small size compared to some competitors
- Dependence on a limited number of key partnerships
- High research and development costs
- Need for continuous innovation to stay ahead in a dynamic industry
- Limited market reach in certain geographic regions
Opportunities
BioArctic AB can leverage various opportunities to further expand its market presence and achieve sustainable growth:
- Rising demand for novel therapies targeting neurodegenerative diseases
- Exploring emerging markets with unmet medical needs
- Potential partnerships and collaborations to enhance research capabilities
- Advancements in technology for improved drug delivery systems
- Growing support from regulatory authorities for innovative treatments
Threats
BioArctic AB should be wary of potential threats that could impact its business operations and future prospects:
- Intense competition from larger pharmaceutical companies
- Uncertainty in regulatory approval processes
- Rapidly evolving market trends and customer preferences
- Potential patent challenges and intellectual property disputes
- Economic fluctuations and market volatility
BioArctic Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
BioArctic historical P/E ratio, EBIT multiple, and P/S ratio
BioArctic annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down BioArctic's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in BioArctic's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare BioArctic's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
BioArctic shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
BioArctic Dividend History
2 years of dividend payments
BioArctic dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current BioArctic forecasts and price targets in September 2026
Analyst Price Targets 2026BioArctic Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 4/25/2024 | -0.69SEK | - | -SEK | - | 2024 Q1 |
| 2/1/2024 | -0.86SEK | - | 11.62 MSEK | - | 2023 Q4 |
| 7/10/2023 | -0.91SEK | - | 0.00SEK | - | 2023 Q2 |
| 4/26/2023 | -0.87SEK | - | 0.00SEK | - | 2023 Q1 |
| 2/3/2023 | -0.83SEK | - | 0.00SEK | - | 2022 Q4 |
| 10/20/2022 | 1.75SEK | 1.54SEK | 214.77 MSEK | - | 2022 Q3 |
| 7/12/2022 | -0.01SEK | -0.52SEK | 54.81 MSEK | - | 2022 Q2 |
| 4/28/2022 | -0.54SEK | -0.50SEK | 5.07 MSEK | - | 2022 Q1 |
| 2/3/2022 | -0.52SEK | -0.22SEK | 7.61 MSEK | - | 2021 Q4 |
| 10/21/2021 | -0.43SEK | -0.43SEK | 7.61 MSEK | - | 2021 Q3 |
EESG©
Eulerpool ESG Scorecard© for the BioArctic stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
BioArctic shareholder structure
| % | Name |
|---|---|
21.98620% | |
13.48771% | |
5.72437% | |
3.15326% | |
2.85224% | |
2.17682% |
BioArctic Executives and Management Board
17 members · avg. age 61 · 59 % women
Ms. Gunilla Osswald (64)
President, Chief Executive Officer
9.80 M SEK
Management
Mr. Mikael Moge (58)
Vice President - Chemistry, Manufacturing and Control
Mr. Anders Martin-Loef (54)
Chief Financial Officer, Company Secretary
Ms. Rebecca Kastell
Vice President, Head of Human Resource
Ms. Biljana Rizoska
Vice President - Research, Head of Research
Ms. Emilie Smith
General Counsel, Head of Legal & IP
Mr. Oskar Bosson (49)
Head of Investor Relations and Communications
Board of Directors
Mr. Lars Lannfelt (76)
Director · since 2023
Dr. Eugen Steiner (71)
Independent Chairman of the Board
Mr. Par Gellerfors (78)
Director
Ms. Cecilia Edstroem (59)
Independent Director
Ms. Charlotta Ljungqvist (64)
Independent Director
Mr. Mikael Smedeby (57)
Independent Director
Frequently asked questions about BioArctic
The business model of BioArctic AB revolves around developing innovative therapies for debilitating neurological disorders. The company specializes in researching, developing, and commercializing drugs based on antibodies and small molecules. BioArctic AB primarily focuses on addressing neurodegenerative diseases like Alzheimer's and Parkinson's by developing disease-modifying treatments. With a strong emphasis on scientific expertise and collaboration with academic institutions, the company aims to bring novel therapies to market that can improve the quality of life for patients and their families. As a result, BioArctic AB is dedicated to driving advancements in neurodegenerative disease research and providing effective treatment options for those in need.
BioArctic AB is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of BioArctic AB in the market include companies such as Biogen Inc., Eli Lilly and Company, and AbbVie Inc. These companies operate in the biopharmaceutical industry and have a similar focus on developing treatments for neurological disorders like Alzheimer's disease, where BioArctic AB specializes. These competitors have their own portfolios of potential drug candidates and are actively engaged in research and development efforts. However, BioArctic AB distinguishes itself through its innovative approaches and collaborations with other pharmaceutical companies, which contribute to its unique position in the market.
BioArctic AB is a Swedish biopharmaceutical company specializing in the research and development of innovative treatments for neurological disorders. Established in 2003, BioArctic has grown into a leading player in the industry, focusing on diseases such as Alzheimer's and Parkinson's. With a strong commitment to enhancing the quality of life for patients, BioArctic combines cutting-edge science and technology to develop novel therapies. The company has an extensive portfolio of proprietary technologies and partnerships with prominent pharmaceutical companies. BioArctic's dedication to advancing neuroscience and delivering life-changing solutions has positioned it as a key player in the field of neurological research and development.
BioArctic AB has achieved several significant milestones. The company successfully developed and received regulatory approvals for its innovative drug candidate, Aduhelm, for the treatment of Alzheimer's disease. In addition, BioArctic AB entered into collaboration agreements with major pharmaceutical companies, such as Eisai and AbbVie, to further advance its product pipeline. The company also achieved positive clinical trial results for its Parkinson's disease drug candidate, BAN2401. Furthermore, BioArctic AB successfully listed on the Nasdaq Stockholm stock exchange, further enhancing its visibility and access to capital markets. These achievements highlight BioArctic AB's commitment to advancing groundbreaking therapies and its strong position in the biopharmaceutical industry.
BioArctic AB is primarily present in Sweden, where its headquarters are located. The company has a significant presence in the Nordic region, including Norway, Denmark, Finland, and Iceland. Additionally, BioArctic AB has expanded its presence globally, with operations and partnerships in various countries and regions. The company's focus on innovative drug development and research has allowed it to establish a strong presence in the biotechnology and pharmaceutical industries on an international scale.
BioArctic AB represents values of innovative research, scientific excellence, and patient-centric approach. With a strong corporate philosophy focused on enhancing the quality of life for patients, BioArctic is dedicated to developing breakthrough treatments for debilitating disorders. By combining expertise in neuroscience and antibody technologies, BioArctic aims to create novel therapeutics and diagnostics for diseases like Alzheimer's and Parkinson's. The company prioritizes integrity, collaboration, and ethical conduct, striving to make a positive impact on society. BioArctic's commitment to scientific advancement and improving patients' well-being has cemented its position as a leading player in the field of biotechnology.
Analysts currently set an average price target of 326.27 SEK for the BioArctic stock (median: 345.27 SEK), implying +1.3 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the BioArctic stock: 9 recommend buying, 1 holding and 1 selling. For 2026, analysts expect BioArctic to generate revenue of 1.54 B SEK and earnings per share of 5.74 SEK.
Converted at the current exchange rate, the BioArctic share trades at 28.20 EUR (318.20 SEK).
The BioArctic share (BIOA B.ST) is listed on 7 stock exchanges, including: London (0RV2.L), Frankfurt (B9A.F), München (B9A.MU), Düsseldorf (B9A.DU), Stockholm (BIOA B.ST).
BioArctic AB is a Swedish biotechnology company specializing in the development of therapeutics for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company was founded in 2003 and is headquartered in Stockholm, Sweden. The business model of BioArctic is based on three main areas: 1. Product development BioArctic is working on developing new and innovative therapeutic solutions for neurodegenerative diseases. The company collaborates closely with leading scientists and experts in the field to develop new inhibitors and antibodies that can protect the nervous system and stop degenerative processes. An important part of BioArctic's product development process is the clinical phase. The company conducts clinical trials on patients to test the effectiveness of these therapeutics and ensure their safety. 2. Licensing and partnerships BioArctic is also active in the licensing and partnerships space. The company collaborates with other biotechnology or pharmaceutical companies that have an interest in its technologies and products. This allows BioArctic to share its research and development costs and expand its reach in the market. Through partnerships with other companies, BioArctic can also gain access to exclusive technologies and know-how that complement its own capabilities and increase its competitiveness. 3. Licensing out In addition to partnering and collaborating with other companies, BioArctic also licenses its own technologies and products to other companies. The company has already licensed its technology to several companies in the United States, Europe, and Asia. BioArctic's products are highly innovative and unique. The company's flagship product is Aduhelm, an antibody against beta-amyloid plaques that accumulate in the brain and can lead to Alzheimer's disease. Aduhelm was approved by the U.S. Food and Drug Administration (FDA) in June 2021 for the treatment of Alzheimer's disease. BioArctic receives a licensing fee and/or royalties for the use of its technology and the commercial exploitation of the product by the licensed companies. In addition to Aduhelm, BioArctic is also developing other innovative therapeutics such as BAN0805, which aims to degrade alpha-synuclein in the brain fluid. These products are still in development and require further clinical trials before they can be brought to market. In conclusion, BioArctic AB has a successful business model that focuses on the development and commercialization of therapeutic solutions for neurodegenerative diseases. The company collaborates closely with leading scientists and experts in the field to develop innovative products. BioArctic also leverages licensing and partnership agreements to acquire new technologies and capabilities and place its products in the market. The FDA approval of Aduhelm in 2021 has demonstrated BioArctic's potential, with the hope that the company's technology will bring further therapies to the market in the future.
The expected revenue of BioArctic is 1.54 B SEK. This figure is based on current financial data and reflects the company's business performance.
The expected profit of BioArctic is 507.17 M SEK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of BioArctic is currently 55.39. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BioArctic stock.
The price-to-sales ratio (P/S) of BioArctic is currently 18.18. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BioArctic stock.
The Eulerpool Quality Score for BioArctic is 6/10.
The ISIN of BioArctic is SE0010323311. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of BioArctic is A2H5GS. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of BioArctic is BIOA B.ST. The ticker symbol is used to trade BioArctic shares on the stock exchange.
Over the past 12 months, BioArctic paid a dividend of 1.50 SEK . This corresponds to a dividend yield of about 0.47 %. For the coming 12 months, BioArctic is expected to pay a dividend of 2.40 SEK.
The current dividend yield of BioArctic is 0.47 %.
BioArctic paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 2.40 SEK are expected. This corresponds to a dividend yield of 0.75 %.
BioArctic is assigned to the 'Health' sector.
To receive the latest dividend of BioArctic from 6/4/2026 amounting to 2 SEK, you needed to have the stock in your portfolio before the ex-date on 5/29/2026.
The last dividend was paid out on 6/4/2026.
In the year 2019, BioArctic distributed 1.5 SEK as dividends.
The dividends of BioArctic are distributed in SEK.
BioArctic stock
BioArctic Peer Group
BioArctic Ticker
BioArctic FIGI
All fundamentals and in-depth analysis of BioArctic
Our stock analysis for BioArctic stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioArctic. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.